VEA
AKCA

Virtus ETF Advisers’s Akcea Therapeutics Inc AKCA Stock Holding History

Virtus ETF Advisers’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-43,813
Closed -$795K – 370
2020
Q3 		$795K Buy
43,813
+3,690
+9% +$52.3K 0.42% 93
2020
Q2 		$550K Buy
40,123
+9,637
+32% +$149K 0.26% 135
2020
Q1 		$436K Sell
30,486
-2,573
-8% -$42.2K 0.18% 185
2019
Q4 		$560K Buy
33,059
+21,948
+198% +$408K 0.09% 196
2019
Q3 		$171K Sell
11,111
-619
-5% -$13.2K 0.03% 271
2019
Q2 		$275K Buy
11,730
+3,203
+38% +$79.1K 0.06% 255
2019
Q1 		$242K Sell
8,527
-1,083
-11% -$31.5K 0.51% 80
2018
Q4 		$290K Sell
9,610
-9,819
-51% -$275K 0.05% 122
2018
Q3 		$680K Sell
19,429
-13,886
-42% -$420K 0.07% 79
2018
Q2 		$790K Sell
33,315
-6,036
-15% -$144K 0.7% 36
2018
Q1 		$1.01M Buy
39,351
+21,280
+118% +$458K 0.87% 39
2017
Q4 		$314K Buy
+18,071
New +$354K 0.39% 118

Virtus ETF Advisers's AKCA Position: Q4 2020 in Review

Virtus ETF Advisers sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 43,813 shares — an estimated $795K sold.

Virtus ETF Advisers first reported a position in AKCA in Q4 2017 and held it in 12 quarters. The position peaked at $1.01M in Q1 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Virtus ETF Advisers reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Virtus ETF Advisers sold 43,813 Akcea Therapeutics Inc shares in Q4 2020, an estimated $795K.
  • Virtus ETF Advisers first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 12 quarters.
  • Virtus ETF Advisers's Akcea Therapeutics Inc position peaked at $1.01M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.